Skip to main content
PRE
NASDAQ Life Sciences

Prenetics CFO Stephen Lo to Step Down December 30; IM8 CFO Brian Rosin Named Successor

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$18.23
Mkt Cap
$300.814M
52W Low
$11.365
52W High
$27.24
52W Position info
60% above low
Off High info
33% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PRE sits 60% above its 52-week low of $11.365.

Summary

Prenetics' CFO Stephen Lo resigned effective December 30, 2026, and IM8 (US) CFO Brian Rosin is slated to take over as principal financial and accounting officer the next day, pending board approval. The handover lands just as IM8 growth guidance and a $1 billion financing facility put finance execution in focus.


Key Events · Executive and Board Changes · PRE

  • CFO Resignation Effective December 30

    Stephen Hoi Chun Lo tendered his resignation on October 30, 2026, effective December 30, 2026, to pursue new opportunities after eight years as CFO. He will continue in the role until then and afterward serve in an advisory capacity.

  • IM8 CFO Tapped as Successor

    Brian Rosin, currently CFO of IM8 (US) LLC, the company's main operating subsidiary, will become principal financial and accounting officer effective December 31, 2026, subject to board approval and a formal appointment agreement.

  • Handover Timing and Conditions

    The transition is structured with no gap — Lo serves through December 30 and Rosin starts December 31 — but Rosin's appointment is not yet approved or contracted, leaving the parent-level finance role formally open until then.

  • Context: Growth-Stage Finance Load

    The change comes after Q2 2026 revenue of $46.5M (up 288% YoY), FY2026 guidance of $220-230M, initial 2027 IM8 guidance of $400M+, and a $1 billion IM8 growth financing facility with General Catalyst disclosed in August 2026.


Analysis · PRE · Life Sciences

Prenetics is swapping CFOs at a delicate moment. The company just posted its first profitable quarter, raised FY2026 guidance to $220-230M, initiated 2027 guidance of $400M+ for IM8, and is drawing on a $1 billion growth facility from General Catalyst. Lo leaves after eight years and stays on as an adviser; his successor, Brian Rosin, already runs finance at IM8 (US) LLC, the subsidiary driving essentially all of the growth. That continuity argues against a strategic break, but the appointment is not yet final: it needs board approval and a signed agreement, so the parent-level finance leadership remains unsettled until December 31. Rosin also bought roughly $498K of stock in the open market in late August, aligning him with holders.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRE was trading at $18.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.8M. The 52-week trading range was $11.37 to $27.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRE - Latest Insights

PRE
Nov 05, 2026, 8:53 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $15.75 info
Change: -$0.450 (-3%) info
Market Cap: $266.769M info
PRE
Nov 05, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $15.75 info
Change: -$0.450 (-3%) info
Market Cap: $266.769M info
PRE
Oct 13, 2026, 6:53 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $21.16
Real-time Price: $15.75 info
Change: -$5.41 (-26%) info
Market Cap: $266.769M info
PRE
Aug 26, 2026, 8:23 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $22.17
Real-time Price: $15.75 info
Change: -$6.42 (-29%) info
Market Cap: $266.769M info
PRE
Aug 24, 2026, 9:41 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $21.82
Real-time Price: $15.75 info
Change: -$6.07 (-28%) info
Market Cap: $266.769M info